Skip to main content

Table 3 Results of the stratified meta-analyses

From: Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews

Variable

No. of trials/comparisons

SMD

95% CI

I2

Tau2

P for interaction

All trials, physical function

33/43

− 0.50

− 0.61, − 0.40

64%

0.07

Fixed-effect model

 

− 0.53

− 0.57, − 0.45

   

 Intervention

    

0.08

0.42

Pharmacological

 

− 0.53

− 0.64, − 0.42

   

Non-pharmacological

 

− 0.40

− 0.74, − 0.05

   

 Intervention

    

0.08

0.44

Biological treatment

 

− 0.57

− 0.68, − 0.46

   

Other treatment

 

− 0.46

− 0.63, − 0.28

   

All trials, pain

30/41

− 0.48

− 0.66, − 0.30

87%

0.28

Fixed-effect model

 

− 0.50

− 0.56, − 0.44

   

 Intervention

    

0.19

< 0.001

Pharmacological

 

− 0.64

− 0.78, − 0.49

   

Non-pharmacological

 

0.26

− 0.20, 0.72

   

 Intervention

    

0.29

0.28

Biological treatment

 

− 0.64

− 0.80, − 0-49

   

Other treatment

 

− 0.41

− 0.68, − 0.14

   

All trials, spinal mobility

30/45

− 0.32

− 0.48, − 0.17

83%

0.21

Fixed-effect model

 

− 0.32

− 0.38, − 0.26

   

 Intervention

    

0.19

0.28

Pharmacological

 

− 0.35

− 0.51, − 0.19

   

Non-pharmacological

 

− 0.02

− 0.61, 0.56

   

 Intervention

    

0.33

0.65

Biological treatment

 

− 0.31

− 0.47, − 0.15

   

Other treatment

 

− 0.28

− 0.52, − 0.03

   

All trials, spinal stiffness

25/34

− 0.59

− 0.74, − 0.44

75%

0.14

Fixed-effect model

 

− 0.61

− 0.68, − 0.54

   

 Intervention

    

0.18

0.95

Pharmacological

 

− 0.60

− 0.76, − 0.44

   

Non-pharmacological

 

− 0.61

− 0.93, − 0.29

   

 Intervention

    

0.16

0.34

Biological treatment

 

− 0.77

− 0.88, − 0.65

   

Other treatment

 

− 0.55

− 0.75, − 0.35

   

All trials, PGA

21/28

− 0.71

− 0.89, − 0.54

83%

0.18

Fixed-effect model

 

− 0.74

− 0.81, − 0.67

   

 Intervention

    

0.19

0.15

Pharmacological

 

− 0.77

− 0.96, − 0.59

   

Non-pharmacological

 

− 0.37

− 0.81, 0.07

   

 Intervention

      

Biological treatment

 

− 0.84

− 1.09, − 0.60

 

0.20

0.23

Other treatment

 

− 0.60

− 0.87, − 0.34

   

All trials, PJ/E

15/15

0.05

− 0.11, 0.22

68%

0.06

Fixed-effect model

 

0.00

− 0.08, 0.09

   

 Intervention

    

0.00

< 0.001

Pharmacological

 

− 0.06

− 0.15, 0.03

   

Non-pharmacological

 

0.99

0.63, 1.35

   

 Intervention

    

0.04

0.02

Biological treatment

 

− 0.10

− 0.20, − 0.01

   

Other treatment

 

0.27

− 0.10, 0.64

   

All trials, acute phase reactants

27/31

− 0.51

− 0.70, − 0.32

84%

0.22

Fixed-effect model

 

− 0.62

− 0.69, − 0.55

   

 Intervention

    

Pharmacological

 

− 0.51

− 0.70, − 0.32

   

Non-pharmacological

 

   

 Intervention

    

0.12

0.001

Biological treatment

 

− 0.77

− 1.02, − 0.52

   

Other treatment

 

− 0.22

− 0.37, − 0.07

 

−0.07

 

All trials, spine radiographs

1/1

0.96

0.22, 1.69

Fixed-effect model

 

   

 Intervention

    

Pharmacological

 

   

Non-pharmacological

 

   

 Intervention

      

Biological treatment

      

Other treatment

 

0.96

0.22, 1.69

   

All trials, fatigue

3/4

− 0.65

− 0.82, − 0.48

0%

0.00

Fixed-effect model

 

− 0.65

− 0.82, − 0.48

   

 Intervention

    

Pharmacological

 

− 0.65

− 0.82, − 0.48

   

Non-pharmacological

 

   

 Intervention

    

Biological treatment

 

− 0.65

− 0.82, −0.48

   

Other treatment

      
  1. SMD standardized mean difference, CI confidence interval, I2 inconsistency (i.e., the percentage of total variation across studies due to heterogeneity), Tau2 tau squared is an estimate of the variance of the true effect sizes, PJ/E peripheral joint count/enthesitis index